Creative Medical Technology Holdings, Inc.
$2.26
▲
2.16%
2026-04-21 05:58:01
www.creativemedicaltechnology.com
NCM: CELZ
Explore Creative Medical Technology Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$9.13 M
Current Price
$2.26
52W High / Low
$6.25 / $1.5
Stock P/E
—
Book Value
$2.03
Dividend Yield
—
ROCE
-81.64%
ROE
-86.47%
Face Value
—
EPS
$-2.52
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
4
Beta
1.99
Debt / Equity
0.19
Current Ratio
25.97
Quick Ratio
25.97
Forward P/E
-1.59
Price / Sales
1,318.48
Enterprise Value
$0.73 M
EV / EBITDA
-0.12
EV / Revenue
121.16
Rating
None
Target Price
$20
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Evommune, Inc. | $27.97 | — | $988.7 M | — | -39.16% | -54.42% | $33.2 / $13.88 | $6.52 |
| 2. | ImmunityBio, Inc. | $8.01 | — | $8.28 B | — | -58.17% | 71.02% | $12.43 / $1.83 | $-0.49 |
| 3. | Galmed Pharmaceuticals Ltd. | $0.75 | — | $4.81 M | — | -38.45% | -64.21% | $2.68 / $0.41 | $3.49 |
| 4. | Gossamer Bio, Inc. | $0.42 | — | $98.57 M | — | -150.03% | 365.33% | $3.87 / $0.32 | $-0.53 |
| 5. | Atossa Therapeutics, Inc. | $6.17 | — | $50.2 M | — | -94.38% | -62.74% | $19.35 / $3.76 | $4.57 |
| 6. | Bio Green Med Solution, Inc. | $1.19 | — | $6.54 M | 0.93% | 552.16% | -1.28% | $100.8 / $0.73 | $1.27 |
| 7. | Xencor, Inc. | $12.8 | — | $941.6 M | — | -22.77% | -14.07% | $18.69 / $6.92 | $8.84 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -1.95 M | -1.27 M | -1.26 M | -1.66 M | -1.89 M | — |
| Net Profit | -1.89 M | -1.24 M | -1.23 M | -1.64 M | -1.85 M | — |
| EPS in Rs | -0.51 | -0.33 | -0.33 | -0.44 | -0.5 | -0.75 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.01 M | 0.01 M | 0.01 M | 0.09 M |
| Operating Profit | -6.14 M | -5.74 M | -5.62 M | -10.24 M |
| Net Profit | -6 M | -5.49 M | -5.29 M | -10.14 M |
| EPS in Rs | -1.62 | -1.49 | -1.43 | -2.74 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.81 M | 6.67 M | 10.72 M | 19.19 M |
| Total Liabilities | 0.28 M | 0.33 M | 0.37 M | 3.32 M |
| Equity | 7.51 M | 6.34 M | 10.34 M | 15.86 M |
| Current Assets | 7.4 M | 6.14 M | 10.27 M | 18.75 M |
| Current Liabilities | 0.28 M | 0.33 M | 0.37 M | 3.32 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -5.86 M | -5.3 M | -8.03 M | -7.8 M |
| Investing CF | -0.05 M | 6.32 M | 3.45 M | -10.08 M |
| Financing CF | 7.17 M | 1.45 M | -0.27 M | 15.47 M |
| Free CF | -5.86 M | -5.5 M | -8.13 M | -7.8 M |
| Capex | — | -0.2 M | -0.1 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 22.22% | -89.84% | — | — |
| Earnings Growth % | -3.91% | 47.88% | — | — |
| Profit Margin % | -49940.74% | -58739.71% | -11449.26% | — |
| Operating Margin % | -52216.92% | -62445.91% | -11562.5% | — |
| Gross Margin % | 60% | 60% | 67.84% | — |
| EBITDA Margin % | -51212.81% | -61394.98% | -11458.56% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-06-12 | 1:0.1 |
| 2021-11-10 | 1:0.002 |